Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSI-301 versus aflibercept for treatment-naive macular edema secondary to retinal vein occlusion
2020-001061-37Phase 3Terminated
- Sponsor
- Kodiak Sciences
- Start
- Oct 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vein occlusion (RVO) and macular edema comparing KSI-301 with Aflibercept (2 arms). Primary endpoint: Mean change in BCVA from baseline to Week 24. Started Oct 2020; status: terminated.
02
Drugs
tarcocimab tedromeraflibercept
03
Conditions
Vein occlusion (RVO)macular edema
Beyond the preview
Go deeper on 2020-001061-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001061-37.